Cambridge, MA
Summary
This business specializes in the development of precisely targeted therapies for cancer patients, leveraging deep expertise in chemistry and structure-based drug discovery. They focus on designing innovative small molecules that inhibit clinically proven kinase targets, addressing challenges related to resistance and selectivity in cancer treatment. The company collaborates with physician-scientists to identify patient needs and limitations of existing therapies, thereby enhancing treatment options.
Based on content on nuvalent.com
sygnaturediscovery.com
Nottingham, UK
Pharmaceutical Contract Research Organization (CRO)
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
6.4 years — Since Aug 2018
Web Hosting
Platform
E-Mail Provider
Mimecast
NAICS Code
325412
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Pharmaceuticals and Biotechnology
2. Pharmaceutical Preparation Manufacturing
Vendor
Source
Atlassian
TXT Record
DocuSign
TXT Record
Smartsheet
TXT Record
Mimecast
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|